We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCLIN
RNS Number : 9936M
Clinigen Group plc
19 September 2019
19 September 2019
CLINIGEN GROUP PLC
PDMR SHAREHOLDINGS
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company') announces the following PDMR dealings in accordance with Article 19 of the Market Abuse Regulation:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Nick Keher
--------------------- ------------------------------------
2 Reason for the notification
-----------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------- ------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
-----------------------------------------------------------
a) Name Clinigen Group plc
--------------------- ------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
-----------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------- ------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------- ------------------------------------
c) Currency GBP
--------------------- ------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------- ------------------- ---------------
893p per share 3,900 shares
--------------------- ------------------- ---------------
e) Aggregated 3,900 shares
information 893p
- Aggregated GBP34,827
volume
- Price
- Aggregated
total
--------------------- ------------------------------------
f) Date of the 19 September 2019
transaction
--------------------- ------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------- ------------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 1000
& Joint Broker
James Black / Freddie Barnfield / Freddie
Naylor-Leyland
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
/ Rozi Morris Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHLLFVLAEIALIA
(END) Dow Jones Newswires
September 19, 2019 07:37 ET (11:37 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
